Ignite Creation Date:
2024-05-06 @ 1:53 PM
Last Modification Date:
2024-10-26 @ 1:22 PM
Study NCT ID:
NCT04158050
Status:
COMPLETED
Last Update Posted:
2023-12-04
First Post:
2019-11-03
Brief Title:
Comparison of Biologicals in Treatment of Severe Asthma
Sponsor:
Helsinki University Central Hospital
Organization:
Helsinki University Central Hospital
Study Overview
Official Title:
Comparison of Biologicals in Treatment of Severe Asthma - Real Life Experiences
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BiSA
Brief Summary:
This is a retrospective clinical study on adult patients 18 years or more with biological therapy for severe asthma at the Helsinki University Central Hospital HUCH This is a real-life study with a broader patient population than in a randomized controlled trial Omalizumab has been used for treatment of asthma in HUCH since January 2009 anti-IL5 therapies starting with mepolizumab since April 2016
Detailed Description:
The investigators collect and analyse results of anti-IL5IL5R and anti-IgE therapies in asthma until October 2019The investigators compare number of exacerbations number of glucocorticoid courses dose of per oral glucocorticoid number of antibiotic courses need of emergency care and hospitalizations because of asthma before use of biologicals and at the latest visits of the participants when using biologicals
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None